In 2026, first-line treatment for metastatic pancreatic cancer has expanded from two main options to three. Doctors must choose carefully because there is still no perfect biomarker to guide decisions.
The approval of NALIRIFOX in February 2024, based on the NAPOLI 3 trial, added a new standard to existing treatments. The three main frontline regimens are: mFOLFIRINOX, NALIRIFOX, and Gemcitabine plus Nab-paclitaxel. mFOLFIRINOX is often used for patients who are physically strong and can tolerate intensive treatment. NALIRIFOX has shown better survival than gemcitabine/nab-paclitaxel and may be preferred for patients with existing nerve damage because it contains a lower dose of oxaliplatin. Gemcitabine plus nab-paclitaxel remains a good option for patients who do not want a two-day infusion pump or who are joining clinical trials.
Because there are no direct comparison trials between NALIRIFOX and FOLFIRINOX, doctors base their decisions on individual factors. NALIRIFOX tends to cause more gastrointestinal side effects such as diarrhea and nausea, while platinum-based regimens like FOLFIRINOX raise concerns about neuropathy. Genetic testing also matters. Patients with BRCA or PALB2 mutations often benefit more from platinum-based treatments. Practical issues, such as treatment schedule and whether a patient is willing to use a portable infusion pump, also play a role.
Looking ahead, chemotherapy remains the main treatment, but the field is changing quickly. Early data on RAS inhibitors are promising, and experts believe these drugs could move into first-line and even pre-surgery settings within the next five to ten years. Researchers are also studying vaccines and cell-based immunotherapies to overcome pancreatic cancer’s resistance to immunotherapy. For now, clinical trials are still strongly recommended for eligible patients, since current treatments are not yet curative.